Prostate Cancer Trial, Recruiting NCT04420702 Sponsor: Washington University School of Medicine Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT04420702
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are over 18 years of age and are willing and able to give informed consent to participate.
  • People who have not previously been diagnosed with prostate cancer, and who are already scheduled to have a prostate biopsy as part of their normal medical care — this includes people with a raised PSA level and no previous biopsy, as well as those with a raised PSA level and a previous biopsy that came back clear.
  • People who have previously been diagnosed with prostate cancer and are currently being monitored through active surveillance (watchful waiting), and who are already scheduled to have a biopsy as part of their normal medical care.

Who may not be able to join:

  • People who have a medical reason why they cannot have an MRI scan — this includes those with certain metal implants in their body, such as a pacemaker or a heart device called an implantable cardioverter-defibrillator, or a cochlear (hearing) implant.
  • People who experience severe claustrophobia (fear of enclosed spaces) that cannot be managed with medication, making it impossible to undergo an MRI scan.
  • People who are unable to lie flat and still for more than one hour.
  • People who have previously had surgery on the prostate to treat prostate cancer, such as removal of the prostate or a procedure to destroy part of it.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Joseph Ippolito, M.D., Washington University School of Medicine

Phone: 314-362-2925

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
27 February 2020
Est. completion
31 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Area under the curve (AUC) comparison from biopsy and DBSI; Receiver operating characteristic (ROC) comparison from biopsy to DBSI; Prostate sector analysis as measured by comparison of the highest Gleason score from each of the 10 biopsy sectors to the DBSI predicted pathology from each sector

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov